Intranasal Insulin Cuts Postoperative Delirium Risk; 30 IU Appears Optimal
This dose-response meta-analysis of eight randomised trials gives pharmacists in perioperative and critical care practice the first modelled estimate of an effective intranasal insulin dose for delirium prevention, while safety data remain thin.
📅 Journal publication: Dec 2026(online Oct 27, 2026)·Last updated: Nov 8, 2026
Intranasal insulin shows promise in reducing postoperative delirium.
Postoperative delirium (POD) is a common complication with serious outcomes; intranasal insulin could offer a preventive option. Intranasal insulin reduced POD risk (risk ratio 0.39) and showed maximal benefit at 30 international units (IU) with no additional effect at higher doses. The study suggests potential use of intranasal insulin to prevent POD, but further large-scale trials are needed for confirmation before clinical application. Intranasal insulin reduces POD risk most effectively at 30 IU.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Saeed O, Nounou MV, Saeed A, Rochwerg B, Abdelaziz AM, Weinhouse GL, Shim SR, Elhadi M
Citation:Saeed O, Nounou MV, Saeed A, et al. Effect of intranasal insulin on postoperative delirium: A systematic review and dose-response meta-analysis. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. 2026;28(4):100227. doi:10.1016/j.ccrj.2026.100227